Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-27T10:21:26.588Z Has data issue: false hasContentIssue false
  • English
  • Français

Trends in prescription of cardiovascular drugs to children in relation to prevalence of CHD from 1999 to 2016

Published online by Cambridge University Press:  11 July 2018

Christian B. Poulsen  and
Mads Damkjær Open the ORCID record for Mads Damkjær [Opens in a new window]
Christian B. Poulsen
Affiliation:
Department of Cardiology, Regional Hospital West Jutland, Herning, Denmark
Mads Damkjær*
Affiliation:
Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark Department of Paediatrics, Kolding Hospital, Kolding, Denmark
*
Author for correspondence: M. Damkjær, MD, PhD, Department of Paediatrics, Kolding Hospital, Skovvangen 4-8, DK-6000 Kolding, Denmark. Tel: +45 20241827; Fax: +45 76362474; E-mail: mads.damkjaer@dadlnet.dk
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction

Owing to massive improvements in the diagnostics and surgery of children with CHD, fatality has decreased substantially. As more children with CHD survive from infancy into later childhood, more will need medication for chronic heart failure. However, surprisingly little is actually known about which drugs are being used to treat children with CHD, and whether prescription rates and CHD prevalence have changed over time.

Objective

The objective of this study was to assess the total prescription of cardiovascular drugs to children during an 18-year period and to assess concomitant CHD prevalence.

Methods

All prescription data of cardiovascular drugs to children aged 0–19 years were extracted from publicly available databases in Norway and Denmark from 1999 to 2016. This was coupled with data on CHD prevalence and birth rates.

Results

The number of defined daily doses of cardiovascular drugs prescribed to children doubled in the study period. This was because of an increased use of beta blockers, angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers, and anti-arrhythmic agents. The use of some classes of drugs was significantly reduced over time. The prevalence of CHD remained constant in both countries – 80 per 10,000 births.

Conclusion

We show that there is an increase in the overall prescription of cardiovascular drugs to children. Beta blockers, angiotensin-converting enzyme/angiotensin receptor blockers, and anti-arrhythmics account for the largest increase. Birth rates decreased or remained constant together with CHD prevalence, suggesting that the increased use of cardiovascular drugs reflected increased prescription per patient, rather than more patients receiving a constant amount of drugs.

Keywords

Heart failureCHDpharmacological therapy
Type
Original Article
Information
Cardiology in the Young , Volume 28 , Issue 9 , September 2018 , pp. 1136 - 1141
Check for updates
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Poulsen CB, Damkjær M. (2018) Trends in prescription of cardiovascular drugs to children in relation to prevalence of CHD from 1999 to 2016. Cardiology in the Young28: 1136–1141. doi: 10.1017/S1047951118000951

References

1. van der Linde, D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 2241–2247.CrossRefGoogle ScholarPubMed
2. Reller, MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008; 153: 807–813.Google Scholar
3. Oyen, N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M. National time trends in congenital heart defects, Denmark, 1977-2005. Am Heart J 2009; 157: 467–473 e1.Google Scholar
4. Mandalenakis, Z, Rosengren A, Skoglund K, Lappas G, Eriksson P, Dellborg M. Survivorship in children and young adults with congenital heart disease in Sweden. JAMA Intern Med 2017; 177: 224–230.CrossRefGoogle Scholar
5. Chamberlain LJ, Fernandes SM, Saynina O, et al. Variation in use of pediatric cardiology subspecialty care: a total population study in California, 1983 to 2011. J Am Coll Cardiol 2015; 66: 37–44.CrossRefGoogle Scholar
6. Khairy, P, Ionescu-Ittu R, Mackie AS, Abrahamowicz M, Pilote L, Marelli AJ. Changing mortality in congenital heart disease. J Am Coll Cardiol 2010; 56: 1149–1157.CrossRefGoogle ScholarPubMed
7. Rossano, JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail 2012; 18: 459–470.Google Scholar
8. Sacks, CA, Jarcho, JA, Curfman, GD. Paradigm shifts in heart-failure therapy – a timeline. N Engl J Med 2014; 371: 989–991.CrossRefGoogle ScholarPubMed
9. Schranz, D, Voelkel, NF. “Nihilism” of chronic heart failure therapy in children and why effective therapy is withheld. Eur J Pediatr 2016; 175: 445–455.CrossRefGoogle ScholarPubMed
10. Moffett, BS, Price, JF. National prescribing trends for heart failure medications in children. Congenit Heart Dis 2015; 10: 78–85.Google Scholar
11. Berg, CLB, Fenne, HS, Furu, O, et al. Norwegian Prescription Database 2012–2016. 2017. Retrieved April 23 to 25, 2018, from http://www.fhi.no/en.Google Scholar
12. Medstat. MEDSTAT.DK. 2017. Retrieved April 23 to 25, 2018, from http://www.medstat.dk/en.Google Scholar
13. Schmidt, M, Hallas J, Laursen M, Friis S. Data Resource Profile: Danish online drug use statistics (MEDSTAT). Int J Epidemiol 2016; 45: 1401–1402g.Google Scholar
14. EUROCAT Central Database, 2017, EUROCAT Retrieved December 2017, from http://www.eurocat-network.eu/accessprevalencedata/prevalencetables.Google Scholar
15. Statistics Norway. 2018. Retrieved January 28, 2018, from https://www.ssb.no/fodte/ Google Scholar
16. Statistics Denmark. 2018. Retrieved January 28, 2018, from http://www.statistikbanken.dk/statbank5a/selectvarval/saveselections.asp Google Scholar
17. Kirk, R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. J Heart Lung Transplant 2014; 33: 888–909.CrossRefGoogle ScholarPubMed
18. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298: 1171–1179.Google Scholar
19. Poole-Wilson, PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7–13.CrossRefGoogle ScholarPubMed
20. Miyamoto, SD, Stauffer BL, Nakano S, et al. Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. Eur Heart J 2014; 35: 33–41.Google Scholar
21. Rupp, S, Jux, C. Advances in heart failure therapy in pediatric patients with dilated cardiomyopathy. Heart Fail Rev 2018. doi: 10.1007/s10741-018-9692-1Google Scholar
22. Lewis, AB, Chabot, M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol 1993; 14: 9–12.Google Scholar
23. Duboc, D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45: 855–857.CrossRefGoogle ScholarPubMed
24. Elkiran, O, Sandikkaya A, Kocak G, Karakurt C, Taskapan C, Yologlu S. Evaluation by N-terminal prohormone of brain natriuretic peptide concentrations and ross scoring of the efficacy of digoxin in the treatment of heart failure secondary to congenital heart disease with left-to-right shunts. Pediatr Cardiol 2013; 34: 1583–1589.Google Scholar
25. Masarone, D, Valente F, Rubino M, et al. Pediatric heart failure: a practical guide to diagnosis and management. Pediatr Neonatol 2017; 58: 303–312.Google Scholar
26. Gillis, J, Loughlan, P. Not just small adults: the metaphors of paediatrics. Arch Dis Child 2007; 92: 946–947.CrossRefGoogle ScholarPubMed
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 1

Download Poulsen and Damkjær supplementary material(File)
File 52.2 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 2

Download Poulsen and Damkjær supplementary material(File)
File 9.2 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 3

Download Poulsen and Damkjær supplementary material(File)
File 122.3 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 4

Download Poulsen and Damkjær supplementary material(File)
File 9.5 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 5

Download Poulsen and Damkjær supplementary material(File)
File 20.2 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 6

Download Poulsen and Damkjær supplementary material(File)
File 9.3 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 7

Download Poulsen and Damkjær supplementary material(File)
File 127.7 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 8

Download Poulsen and Damkjær supplementary material(File)
File 9.5 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 9

Download Poulsen and Damkjær supplementary material(File)
File 102.4 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 10

Download Poulsen and Damkjær supplementary material(File)
File 28.7 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 11

Download Poulsen and Damkjær supplementary material(File)
File 119.8 KB
Supplementary material: File

Poulsen and Damkjær supplementary material

Poulsen and Damkjær supplementary material 12

Download Poulsen and Damkjær supplementary material(File)
File 28.7 KB